Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A/S Investors
Click here to join the case
LOS ANGELES, July 14, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Orphazyme A/S (“Orphazyme” or “the Company”) (NASDAQ : ORPH) investors that acquired securities in connection with FTA’s June 2021 initial public offering.
It is alleged in this complaint that Orphazyme made misleading and false statements to the market. Orphazyme’s arimoclomol was not an effective treatment for Inclusion Body Myositis (“IBM”). Additionally, Arimoclomol was not an effective treatment for Amyotrophic Lateral Sclerosis (“ALS”). Orphazyme’s new drug application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease type C (“NPC”) was incomplete and require∂ additional data to support its benefit-risk analysis. It was not likely that The FDA would approve the Orphazyme’s NDA for arimoclomol. Orphazyme’s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Orphazyme.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.